Ikena Oncology (IKNA) director Bonita received 153,121 shares

Insider transactions reported

David P Bonita (director at Ikena Oncology Inc., IKNA) reported that they received 153,121 shares on Aug 4, 2023. After these transactions the filing shows 5,582,144 shares held indirectly (See Footnote).

Reporting person

Bonita David P

Options and other derivatives

Holdings before and after

• Non-Voting Common Stock: 5,429,023 to 5,582,144 indirect, See Footnote
• Series A Preferred Stock: 0 to 353,192 indirect, See Footnote

Other positions listed

• Common Stock: 2,098,097 indirect, See Footnote
• Common Stock: 91,014 indirect, See Footnote
• Non-Voting Common Stock: 157,288 indirect, See Footnote

Footnotes from the filing

1. 1. On September 14, 2023, the Reporting Person filed a Form 4 that inadvertently reported the acquisition of shares of the Issuer's common stock rather than shares of Non-Voting Common Stock. This amendment corrects the type of shares of Issuer common stock acquired by the Reporting Person and the amount of securities beneficially owned by the Reporting Person.
2. 2. Each share of Non-Voting Common Stock is convertible into one share of the Issuer's common stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation that may be increased or decreased by the holder upon 61 days' notice to the Issuer.
3. 3. Received in exchange for shares of Class A common stock of Pionyr Immunotherapeutics, Inc. ( Pionyr ) in accordance with the terms of the Agreement and Plan of Merger, dated August 4, 2023, by and among the Issuer, Portsmouth Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Portsmouth Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Pionyr, and Fortis Advisors LLC, as securityholder agent.
4. 4. These securities are held of record by OrbiMed Private Investments VI, LP ( OPI VI ). OrbiMed Capital GP VI LLC ( GP VI ) is the general partner of OPI VI. OrbiMed Advisors LLC ( OrbiMed Advisors ), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
5. 5. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ( Genesis Master Fund ). OrbiMed Genesis GP LLC ( Genesis GP ) is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
6. 6. Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the Exchange Act ), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
7. 7. Following approval by the Issuer's stockholders of the conversion of the Issuer's Series A Preferred Stock into shares of the Issuer's common stock, each share of Series A Preferred Stock is automatically convertible into one share of the Issuer's voting common stock; provided that if a holder of the Issuer's Series A Preferred Stock was a holder of the Issuer's Non-Voting Common Stock prior to such conversion, such holder will receive shares of the Issuer's Non-Voting Common Stock to the extent such conversion would result in such holder beneficially owning more than 9.99% of the Issuer's voting common stock.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ